



MATERNAL HEALTH

New drug regimens for HIV in pregnancy and a national strategic plan to manage HIV: A South African perspective

Nnabuike C. Ngene^a, Jagidesa Moodley^{b,*}^a Department of Obstetrics and Gynecology, Edendale Hospital, Pietermaritzburg, and University of KwaZulu-Natal, Durban, South Africa^b Women's Health and HIV Research Group, University of KwaZulu-Natal, Durban, South Africa

ARTICLE INFO

Keywords:

Antiretroviral
HIV
Mother-to-child transmission
Pregnancy
South Africa
Strategic planning

ABSTRACT

In South Africa, new drug regimens (WHO treatment Option B) used to manage HIV infection in pregnancy and the national strategic plan on HIV have resulted in improved health outcomes. Among these outcomes are reductions in the following: mother-to-child transmission (MTCT) of HIV to 2.4%; maternal deaths attributable to HIV; and adverse reactions due to antiretroviral therapy (ART). The present article describes these new drug regimens and the national strategic HIV management plan, as well as their challenges and the implications of improved health outcomes. Such outcomes imply that further decreases in MTCT of HIV, and HIV attributable maternal deaths are possible if potential challenges are addressed and treatment option B + offered. A confidential enquiry into each case of MTCT is advocated to reduce vertical transmission rates to zero levels.

© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

In 2012, approximately 35.3 (32.2–38.8) million people, 70% of whom were women, were living with HIV infection worldwide; Sub-Saharan Africa accounts for 71% of this figure [1]. In the same year, an estimated 6.1 million people were living in South Africa with HIV infection; this constitutes an overall prevalence rate of 17.9%, making South Africa the country with the highest number of people infected with this retroviral disease [2]. This has translated to a high burden of HIV infection among pregnant women. To lessen this burden, new drug regimens and strategies have been introduced internationally and across nations. For instance, in 2001 the United Nations developed the four-pronged framework for the prevention of mother-to-child transmission (MTCT) of HIV. The components of this framework are primary prevention of HIV infection; prevention of unplanned pregnancies; prevention of MTCT; and the provision of appropriate care, treatment, and support to HIV-infected mothers, their children, and families [3]. In an attempt to improve care, South Africa has developed management guidelines and health policies that have repeatedly been revised based on emerging evidence and the resources available to the country.

The new antiretroviral drug regimens [4] and national strategic plan [5] for the management of HIV in pregnancy in South Africa are leading to improved health outcomes. Notably, the national prevalence of HIV in pregnancy has declined from 30% in 2010 to 29.5% in 2012 [2]. Data on the number of HIV-exposed infants who tested polymerase chain

reaction (PCR) positive at approximately two months of age show that the rate of MTCT has also declined from 9.6% in 2008 to 4.4% in 2010 [6] and to 2.4% in 2013 [7]. The 2013 interim Saving Mothers report has shown that the institutional maternal mortality ratio in South Africa has decreased from 176.2 per 100 000 live births in 2008–2010 to 146.7 per 100 000 live births in 2012. The decline in maternal deaths is attributable to a reduction in the number of deaths resulting from nonpregnancy-related infections, primarily HIV [8]. Similarly, maternal deaths resulting from an adverse reaction to antiretroviral therapy (ART)—nevirapine (NVP) in particular—have also declined [9].

The present article describes South Africa's new drug regimen and national strategic plan used for the management of HIV in pregnancy, their outcomes and challenges, and the implications of further reductions in MTCT rates.

2. WHO treatment options for prevention of mother-to-child transmission of HIV

Different ART options have been used for prevention of mother-to-child transmission (PMTCT) of HIV [10]. In 2012, WHO introduced three management categories: option A, option B, and option B + [11].

2.1. Option A

Triple antiretroviral drugs (ARVs) are started following diagnosis and continued for life (life-long) if the pregnant woman has a CD4 count less than or equal to 350 cells/mm³. Pregnant women with a CD4 count greater than 350 cells/mm³ receive zidovudine (AZT) from

* Corresponding author at: Women's Health and HIV Research Group, University of KwaZulu-Natal, Durban, South Africa. Tel.: +27 31 260 4675.

E-mail address: jmog@ukzn.ac.za (J. Moodley).

14 weeks of gestation in the prenatal period; single-dose NVP, AZT, and lamivudine (3TC) during labor; and AZT plus 3TC for seven days postpartum. The infants of these mothers receive daily NVP for an extra week following cessation of breastfeeding, or for 4–6 weeks (if not being breastfed or if the mother is on life-long ARVs).

2.2. Option B

Life-long triple ARVs are started following diagnosis in women with CD4 less than or equal to 350 cells/mm³. In women with CD4 greater than 350 cells/mm³, triple ARVs are commenced from 14 weeks of gestation throughout the prenatal period and stopped after childbirth (if not breastfeeding), or continued up to one week after cessation of breastfeeding. The infants of these mothers receive daily NVP or AZT until they are 4–6 months old irrespective of infant feeding practices.

2.3. Option B +

Every pregnant woman diagnosed with HIV infection is commenced on life-long triple ARVs irrespective of CD4 count. The infants of these mothers receive daily NVP or AZT until they are 4–6 months old regardless of infant feeding practices.

2.4. Rationale behind the different treatment options

Treatment options A, B, and B + were suggested by WHO for the following reasons: the global plan to eliminate new cases of HIV infection in children by 2015 and the need to keep infected mothers alive; attempt to reduce HIV transmission among discordant couples; operational challenges associated with option A and option B; some countries proposing their wish to adopt option B +; initiative to simplify ARV regimen to be exactly the same as the national first-line ART for non-pregnant adults and avoid the need to unnecessarily change ARV during a pregnancy; data suggesting that efavirenz is safe in pregnancy; and increasing affordability of ARVs [11]. It has also been established that NVP causes adverse reactions, especially hepatotoxicity, at baseline CD4 counts of greater than 250 cells/mm³ and greater than 400 cells/mm³ in women [12] and men [13], respectively. In addition, an increasing incidence of cases of hepatic failure and Stevens-Johnson syndrome has been detected in pregnant patients on NVP [9]. The availability of a single pill containing a fixed-dose combination of tenofovir, lamivudine, and efavirenz has simplified the ARV regimen and efficiency [11].

2.5. Probability of vertical HIV transmission with the use of different treatment options

There is a scarcity of studies that assess transmission probabilities when all aspects of each WHO treatment option are addressed in the targeted population [14,15]. However, use of mathematical models, such as Spectrum, shows the following MTCT probabilities: single-dose NVP, 9.4%–12.1%; WHO 2006 dual therapy, 2.3%–5.3%; option A, 2%; option B, 0.9%–2.9%; and option B +, less than 2% [15].

3. New PMTCT drug regimens in South Africa

The use of ARVs for PMTCT was first introduced in South Africa as national policy in 2002. The regimen involved the administration of single-dose NVP to both the mother (during labor) and her newborn (after delivery). Since then, the PMTCT program was modified in 2005 and 2008, and option A was introduced in 2010 [16]. Thereafter, option B was introduced in 2013 and constitutes current practice at the time of writing the present article [4]. The current drug regimen in South Africa is similar to WHO option B with the exception that South African guidelines state that pregnant women with CD4 greater than 350 cell/mm³ are initiated on ART during the first prenatal visit, even before 14 weeks of gestation. This South African drug regimen is satisfactory (as option B) given the acceptable safety profile of efavirenz in pregnancy, and that the longer the duration of ART before delivery then the less chance of MTCT of HIV [17]. Table 1 provides a summary of the ARV regimen used for PMTCT in South Africa. Further details on the drug regimens used for PMTCT in South Africa are free to view online [4]. The purpose of the South African PMTCT guidelines is to ensure that every possible preventable MTCT, using option B, is achieved.

4. South African national strategic plan on HIV

Strategic planning may be defined as “the systematic and organized process whereby an organization creates a document indicating the way it plans to progress from its current situation to the desired future situation” [18]. Several approaches have been used to develop strategic planning. A common classical method involves the following five processes: (1) establishing mission, vision, and values; (2) strategy formulation involving an analysis of internal and external environments, SWOT (strengths, weaknesses, opportunities, and threats) matrix, strategic alternatives, areas and objectives; (3) operational planning; (4) evaluation of results; and (5) strategy reformulation [18].

Table 1

Summary of antiretroviral therapy approved for prevention of mother-to-child transmission of HIV in South Africa in 2013.

Recipient	Antiretroviral therapy
Mother	All pregnant women except those already known to be HIV infected undergo Provider Initiated Counselling and Testing during the first prenatal visit. HIV-infected women are then managed as outlined below. Women who are HIV infected are started on fixed-dose combination (FDC) of TDF, FTC/3TC, EFV the same day (in the absence of active psychiatric or renal disorder) and reviewed in one week. Women with contraindication to FDC (such as active psychiatric or renal disorder) are started on daily AZT (300 mg) the same day as long as the hemoglobin is greater than 7 g/dL. Following a review in one week, they are placed on appropriate regimen. Women on FDC with a baseline CD4 count less than or equal to 350 cell/mm³ or WHO clinical stage 3/4 disease, the treatment is continued life-long. Women on FDC with a baseline CD4 count greater than 350 cell/mm³ or WHO clinical stage 1/2 disease, the treatment is continued throughout the prenatal and intrapartum period until one week after complete cessation of breastfeeding. Women having renal impairment with CD4 less than or equal to 350 cells/mm³ or WHO stage 3/4 are later commenced on FDC unless the serum creatinine is greater than 85 μmol/L, in which case they receive a renal-friendly regimen, AZT + 3TC + EFV for life (but ABC or d4T is used if AZT is contraindicated). With a CD4 count greater than 350 cell/mm³ or WHO clinical stage 1/2 disease, the patient receives daily AZT prenatally, AZT 3 hourly plus sd NVP and sd TDF/FTC intrapartum. Women having psychiatric disorder with CD4 less than or equal to 350 cells/mm³ or WHO stage 3/4 are commenced on life-long TDF + FTC + NVP (or LPV/RTV if CD4 greater than 250 cells/mm³). With a CD4 count greater than 350 cell/mm³ or WHO clinical stage 1/2 disease, the patient receives: prenatally AZT daily; intrapartum AZT 3 hourly plus sd NVP and sd TDF/FTC. Women who test HIV positive for the first time in labor are given sd NVP plus AZT 3 hourly and sd TDF + FTC.
Infants	Infants born to HIV-infected mothers receive daily NVP for at least six weeks or until one week after cessation of breastfeeding.^a

Abbreviations: AZT, Zidovudine; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; LPV/RTV, lopinavir/ritonavir; NVP, nevirapine; sd, single dose; TDF, tenofovir; 3TC, lamivudine.

^a Mixed feeding is not a recommended infant feeding option.

Download English Version:

<https://daneshyari.com/en/article/3951647>

Download Persian Version:

<https://daneshyari.com/article/3951647>

[Daneshyari.com](https://daneshyari.com)